🔥 Shingles Antiviral Treatment Window Simulator

Rash Onset — The Clock Starts Ticking

Placeholder: dermatomal vesicular rash marks hour zero of the treatment window.

• 1–5 days: Typical prodrome (Placeholder pain/tingling phase)
• Dermatomal: Rash pattern (Placeholder unilateral band)
• Day 3–5: Peak vesicle stage (Placeholder crusting follows)
• Dorsal root ganglia: VZV reactivation site (Placeholder latent virus site)

Detecting rash onset

Placeholder: onset marks the reference point for the 72-hour clock.

The 72-Hour Treatment Window

Placeholder: antivirals are most effective when started within 72 hours.

• 72 hours: Critical window (Placeholder from rash onset)
• IDSA/AAD: Guideline source (Placeholder clinical guidance)
• Efficacy drops: Window closes (Placeholder sharp decline)
• <48h: Best case start (Placeholder optimal timing)

Why 72 hours matters

Placeholder: viral replication in ganglia slows after this point, reducing drug impact.

Early Antiviral Initiation Benefit

Placeholder: early dosing flattens the severity curve and shortens illness.

• Up to 45%: Rash duration cut (Placeholder with early start)
• Up to 60%: PHN risk cut (Placeholder with early start)
• >90%: Viral suppression (Placeholder early treatment)
• Marked: Pain reduction (Placeholder acute neuritis)

Mechanism of benefit

Placeholder: nucleoside analogs block viral DNA polymerase early in replication.

Late Initiation — Reduced Benefit

Placeholder: starting after 72 hours yields diminishing therapeutic return.

• Sharp: Efficacy decay (Placeholder past 72h)
• Some to 120h: Residual benefit (Placeholder fading window)
• Minimal: Beyond 120h (Placeholder little added value)
• Elevated: Complication risk (Placeholder higher PHN odds)

Why delay hurts

Placeholder: viral replication has largely peaked, limiting antiviral effect.

Outcome Comparison — Duration & PHN Risk

Placeholder: compare treated vs untreated outcomes across timing scenarios.

• ~20%: Untreated PHN risk (Placeholder older adults)
• ~8%: Early-treated PHN risk (Placeholder within window)
• Faster: Rash resolution (Placeholder early treatment)
• Famciclovir/Valacyclovir: Best drug choice (Placeholder higher potency)

Summary comparison

Placeholder: timing matters more than drug choice, but both compound benefit.

Placeholder: earliest treatment within the window gives the best combined outcome.